Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades. Mar-04-20 07:18AM, An Intrinsic Calculation For BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN) Suggests It's 26% Undervalued Simply Wall St. Feb-27-20 10: BioMarin Pharmaceutical Inc. Industry: Health Care - Major Pharmaceuticals Stock Symbol: BMRN - NASDAQ Indexes: Nasdaq 100 Animal Usage BioMarin Pharmaceutical (NASDAQ:BMRN) is set to report fourth-quarter and full -year 2019 results on Feb 26, after market close. In the last reported quarter, the BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan , M.D., Ph.D., has been named to the San Francisco Business Times 6 days ago National Hemophilia Foundation Rings the Nasdaq Opening Bell.
Latest Biomarin Pharmaceutical Inc (BMRN:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and 24 Nov 2014 BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. ( Nasdaq:RNA) today announced that they have entered into a
Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades. Mar-04-20 07:18AM, An Intrinsic Calculation For BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN) Suggests It's 26% Undervalued Simply Wall St. Feb-27-20 10: BioMarin Pharmaceutical Inc. Industry: Health Care - Major Pharmaceuticals Stock Symbol: BMRN - NASDAQ Indexes: Nasdaq 100 Animal Usage BioMarin Pharmaceutical (NASDAQ:BMRN) is set to report fourth-quarter and full -year 2019 results on Feb 26, after market close. In the last reported quarter, the BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Brinda Balakrishnan , M.D., Ph.D., has been named to the San Francisco Business Times 6 days ago National Hemophilia Foundation Rings the Nasdaq Opening Bell. 31 May 2016 BioMarin (NASDAQ: BMRN) faced regulatory roadblocks in its attempts to win approval for its drug, called drisapersen or Kyndrisa, in the
The rare-disease specialist BioMarin Pharmaceutical (NASDAQ:BMRN) posted an outstanding third-quarter earnings report yesterday after the closing bell. Specifically, the biotech crushed FactSet's
As of 1:00 PM PDT Mar 18 on the NASDAQ ∙ Minimum 15 minute delay. Profile. News Q1 2020 Biomarin Pharmaceutical Inc Earnings Release Apr 23, 2020